{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T14:35:06Z","timestamp":1693578906229},"reference-count":43,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.2169\/internalmedicine.9857-17","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T22:21:34Z","timestamp":1515622894000},"page":"1533-1542","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study"],"prefix":"10.2169","volume":"57","author":[{"given":"Akira","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Ichiki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japan Community Health care Organization Kyushu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, JR Kyushu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Yanagita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saiseikai Karatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamanomachi Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Dohmen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chihaya Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[{"name":"The Center for Liver Disease, Shin-Kokura Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Medicine, Fukuoka Sanno Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695, 1998.","DOI":"10.1002\/hep.510280632"},{"key":"2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon \u03b1-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol 27: 1233-1240, 2012.","DOI":"10.1111\/j.1440-1746.2011.06965.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol 89: 441-452, 2014.","DOI":"10.1016\/j.bcp.2014.04.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: 1879-1888, 2014.","DOI":"10.1056\/NEJMoa1402355"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889-1898, 2014.","DOI":"10.1056\/NEJMoa1402454"},{"key":"7","unstructured":"7. Bourli\u00e8re M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15: 397-404, 2015."},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Reddy KR, Bourli\u00e8re M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62: 79-86, 2015.","DOI":"10.1002\/hep.27826"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 66: 153-194, 2017.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62: 932-954, 2015.","DOI":"10.1002\/hep.27950"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 10: 702-726, 2016.","DOI":"10.1007\/s12072-016-9717-6"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15: 645-653, 2015.","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 21: 762-768, 2014.","DOI":"10.1111\/jvh.12312"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649, 1973.","DOI":"10.1002\/bjs.1800600817"},{"key":"15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"15. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149: 649-659, 2015.","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Deterding K, H\u00f6ner Zu, Siederdissen C, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 42: 889-901, 2015.","DOI":"10.1111\/apt.13343"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Miyaki E, Imamura M, Hiraga N, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res 46: 758-764, 2016.","DOI":"10.1111\/hepr.12621"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64: 1224-1231, 2016.","DOI":"10.1016\/j.jhep.2016.01.029"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 65: 524-531, 2016.","DOI":"10.1016\/j.jhep.2016.05.010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373: 2618-2628, 2015.","DOI":"10.1056\/NEJMoa1512614"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat 23: 408-418, 2016.","DOI":"10.1111\/jvh.12534"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16: 685-697, 2016.","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1. Hepatol Res 44 (Suppl S1): 59-70, 2014.","DOI":"10.1111\/hepr.12272"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19: 1321-1324, 1994.","DOI":"10.1016\/0270-9139(94)90887-7"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"26","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"26. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526, 2003.","journal-title":"Hepatology","ISSN":"http:\/\/id.crossref.org\/issn\/0270-9139","issn-type":"print"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20: 15-20, 1994.","DOI":"10.1016\/0270-9139(94)90128-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41: 1376-1382, 2005.","DOI":"10.1002\/hep.20717"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int 1: 2-20, 2010.","DOI":"10.1007\/s13340-010-0006-7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124: 3352-3363, 2014.","DOI":"10.1172\/JCI75938"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Nagaishi K, Ataka K, Echizen E, Arimura Y, Fujimiya M. Mesenchymal stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow-derived cells. Hepatology 59: 1816-1829, 2014.","DOI":"10.1002\/hep.26975"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wan Y, Garner J, Wu N, et al. Role of stem cells during diabetic liver injury. J Cell Mol Med 20: 195-203, 2016.","DOI":"10.1111\/jcmm.12723"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis 11: 105-117, 2007.","DOI":"10.1016\/j.cld.2007.02.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 6: 864-876, 2008.","DOI":"10.1016\/j.cgh.2008.03.024"},{"key":"35","first-page":"609","volume":"55","author":"S Takamatsu","year":"2008","unstructured":"35. Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 55: 609-614, 2008.","journal-title":"Hepatogastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0172-6390","issn-type":"print"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30: 734-743, 2007.","DOI":"10.2337\/dc06-1539"},{"key":"37","unstructured":"37. Matsunami T, Sato Y, Ariga S, et al. Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Int J Clin Exp Pathol 3: 472-481, 2010."},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278, 2004.","DOI":"10.1002\/hep.20051"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Shiraishi H, Okamoto H, Yoshimura A, Yoshida H. ER stress-induced apoptosis and caspase-12 activation occurs downstream of mitochondrial apoptosis involving Apaf-1. J Cell Sci 119: 3958-3966, 2006.","DOI":"10.1242\/jcs.03160"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Cunard R, Sharma K. The endoplasmic reticulum stress response and diabetic kidney disease. Am J Physiol Renal Physiol 300: F1054-F1061, 2011.","DOI":"10.1152\/ajprenal.00021.2011"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Zhang Q, Li Y, Liang T, et al. ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice. Int J Biol Sci 11: 559-568, 2015.","DOI":"10.7150\/ijbs.10690"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Solomon SS, Odunusi O, Carrigan D, et al. TNF-alpha inhibits insulin action in liver and adipose tissue: a model of metabolic syndrome. Horm Metab Res 42: 115-121, 2010.","DOI":"10.1055\/s-0029-1241834"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 28: 179-185, 2010.","DOI":"10.1159\/000282083"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/11\/57_9857-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T06:52:20Z","timestamp":1570603940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/11\/57_9857-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9857-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}